Recent Updates
Recently added Catalysts

Brensocatib

Phase 3

Non-Cystic Fibrosis Bronchiectasis | Small molecule | Respiratory |Insmed Incorporated|Last Updated: Dec 16, 2025

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindPLACEBO_CONTROLLEDDMCBiomarker
Total Trials2
Total Enrollment2,023
FDA Designations
No designations recorded
Clinical Trials (2)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT04594369A Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib in Participants With Non-Cystic Fibrosis BronchiectasisPHASE3 COMPLETED 1,767Dec 1, 2020Oct 28, 2024Dec 16, 2025373 United States, Argentina +34
NCT03218917Assessment of INS1007 in Participants With Non-Cystic Fibrosis BronchiectasisPHASE2 COMPLETED 256Oct 31, 2017Dec 12, 2019Mar 27, 2023108 United States, Australia +12
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Annualized Rate of Pulmonary Exacerbations (PEs)
Up to Week 52

PE was defined as having 3 or more of these symptoms for at least 48 hours resulting in a physician's decision to prescribe antibiotics: 1. Increased cough 2. Increased sputum volume or change in sputum consistency 3. Increased sputum purulence 4. Increased breathlessness and/or decreased exercise tolerance 5. Fatigue and/or malaise 6. Hemoptysis. A severe pulmonary exacerbation was that required intravenous (IV) antibacterial drug treatment and/or hospitalization. A minimum of 14 days must have occurred between one exacerbation onset and the next. Any exacerbation that occurred less than 14 days from the prior exacerbation was not considered a new exacerbation. Independent adjudication committee with pulmonary physicians adjudicated reported PE events to see if they fulfil the protocol definition. The rate of PE was analyzed using the negative binomial model.

Time to the First Pulmonary Exacerbation Over 24-Week Treatment Period
Baseline (Day 1) to Week 24

Time to first pulmonary exacerbation was calculated as the number of days from the date of randomization to the date of first documentation of an exacerbation. Pulmonary exacerbation was defined as having 3 or more of the following symptoms for at least 48 hours resulting in a physician's decision to prescribe antibiotics: 1. Increased cough 2. Increased sputum volume or change in sputum consistency 3. Increased sputum purulence 4. Increased breathlessness and/or decreased exercise tolerance 5. Fatigue and/or malaise 6. Hemoptysis A minimum of 4 weeks must have occurred between one exacerbation onset and the next. Any exacerbation that occurred less than 4 weeks from the prior exacerbation was not considered a new exacerbation. The analysis was performed using the stratified log rank test and using Kaplan Meier (KM) curves.

Secondary Endpoints
Time to First PE
Up to Week 52
Responder Status for Exacerbation-Free Over the 52-Week Treatment Period
Up to Week 52
Change From Baseline at Week 52 in Postbronchodilator Forced Expiratory Volume in 1 Second (FEV1)
Baseline, Week 52
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingDOUBLE
ModelPARALLEL
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
Brensocatib 10 milligrams (mg)EXPERIMENTALParticipants will receive brensocatib 10 mg, tablets orally, once daily, for 52 weeks.
Brensocatib 25 mgEXPERIMENTALParticipants will receive brensocatib 25 mg, tablets orally, once daily, for 52 weeks.
PlaceboPLACEBO_COMPARATORParticipants will receive a brensocatib-matching placebo, tablets orally, once daily, for 52 weeks.
Brensocatib 10 mgEXPERIMENTALParticipants received brensocatib 10 mg once daily (QD) before breakfast, for 24 weeks.
Interventions
NameTypeDescription
Brensocatib 10 mgDRUGOral tablet.
Brensocatib 25 mgDRUGOral tablet.
PlaceboDRUGBrensocatib-matching oral tablet.
Unlock Study Design Details
Eligibility Criteria
Age Range12 Years — 85 Years
SexALL
Healthy VolunteersNo
Study Sites373

Inclusion Criteria: 1. Provide their signed study informed consent to participate. a. Adolescent participants must have signed study assent form to participate, and the adolescent's parent or legal guardian must have provided signed informed consent for the adolescent to participate. 2. Clinica...

Countries:United StatesArgentinaAustraliaAustriaBelgiumBrazilBulgariaCanadaChileColombiaDenmarkFranceGermanyGreeceHungaryIrelandIsraelItalyJapanLatviaMalaysiaMexicoNetherlandsNew ZealandPeruPolandPortugalSerbiaSlovakiaSouth KoreaSpainTaiwanThailandTurkey (Türkiye)UkraineUnited KingdomSingapore
Unlock Eligibility Criteria